DexCom Director Nicholas Augustinos Files Form 144 to Sell $549K in Common Stock

Executive Summary

On September 15, 2026, Nicholas Augustinos, a Director at DexCom, Inc. ($DXCM), filed a Form 144 notice of proposed sale covering 6,539 shares of common stock with an aggregate market value of approximately $549,538.

Key Transaction Highlights

• Securities Offered: 6,539 Common Shares
• Market Value: $549,537.56 (~$84.04 per share)
• Shares Outstanding: 377,360,765 shares (proposed sale represents <0.01% of total shares outstanding)
• Trading Plan: Executed pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2026
• Broker: Fidelity Brokerage Services LLC
• Source of Shares:
  • 3,496 shares acquired via vested RSU grant on May 8, 2026
  • 3,043 shares acquired via vested RSU grant on May 19, 2022

Recent Trading Activity

In the past three months, the insider reported selling:

• 1,550 shares on September 14, 2026, generating gross proceeds of $130,231.00.

Significance Assessment

The trading significance is assessed as Low. The proposed transaction is modest in size relative to DexCom's outstanding share base and is conducted under a pre-established Rule 10b5-1 trading arrangement covering shares acquired through director equity compensation grants.